Main reports of treatment of CML with IFN-α alone or in combination with HU
| Reference . | No. of cases . | No. of CCgR . | Study and dose . |
|---|---|---|---|
| Talpaz et al4 1991 and Kantarjian et al51995 | 274 | 72 (26%) | Single center, standard dose |
| Ozer et al33 1993 | 107 | 14 (13%) | Multicenter, variable dose |
| ICSG on CML6 171994 and 1998 | 218 | 23 (10%) | Multicenter, randomized, standard dose |
| Hehlmann et al71994 | 133 | 6 (5%) | Multicenter, randomized, standard dose |
| Schofield et al34 1994 | 41 | 3 (7%) | Single center, low dose |
| Allan et al8 1995 | 293 | 17 (6%) | Multicenter, randomized, standard dose |
| Ohnishi et al9 1995 | 85 | 7 (8%) | Multicenter, randomized, standard dose |
| Montastruc et al35 1995 and Mahon et al37 1998 | 113 | 37 (33%) | Single center, standard dose |
| Thaler et al36 1996 | 74 | 6 (8%) | Multicenter, low dose |
| Guilhot et al291997 | 314 | 28 (9%) | Multicenter, randomized, standard dose |
| BENELUX CML Study Group10 1998 | 100 | 9 (8%) | Multicenter, randomized, low dose |
| ICSG on CML18 1999 | 272 | 28 (10%) | Multicenter, standard dose |
| Steegmann et al38 1999 | 132 | 25 (19%) | Multicenter, standard dose |
| Kloke et al192000 | 71 | 9 (13%) | Single center, standard dose |
| Total | 2227 | 284 (13%) |
| Reference . | No. of cases . | No. of CCgR . | Study and dose . |
|---|---|---|---|
| Talpaz et al4 1991 and Kantarjian et al51995 | 274 | 72 (26%) | Single center, standard dose |
| Ozer et al33 1993 | 107 | 14 (13%) | Multicenter, variable dose |
| ICSG on CML6 171994 and 1998 | 218 | 23 (10%) | Multicenter, randomized, standard dose |
| Hehlmann et al71994 | 133 | 6 (5%) | Multicenter, randomized, standard dose |
| Schofield et al34 1994 | 41 | 3 (7%) | Single center, low dose |
| Allan et al8 1995 | 293 | 17 (6%) | Multicenter, randomized, standard dose |
| Ohnishi et al9 1995 | 85 | 7 (8%) | Multicenter, randomized, standard dose |
| Montastruc et al35 1995 and Mahon et al37 1998 | 113 | 37 (33%) | Single center, standard dose |
| Thaler et al36 1996 | 74 | 6 (8%) | Multicenter, low dose |
| Guilhot et al291997 | 314 | 28 (9%) | Multicenter, randomized, standard dose |
| BENELUX CML Study Group10 1998 | 100 | 9 (8%) | Multicenter, randomized, low dose |
| ICSG on CML18 1999 | 272 | 28 (10%) | Multicenter, standard dose |
| Steegmann et al38 1999 | 132 | 25 (19%) | Multicenter, standard dose |
| Kloke et al192000 | 71 | 9 (13%) | Single center, standard dose |
| Total | 2227 | 284 (13%) |
The table lists, ordered by the year of the first relevant publication, the main reports of the treatment of CML with IFN-α (alone or in combination with HU), for a total of 2227 cases from 10 multicenter prospective studies and 4 single center studies. The total number of CCgR is 284 (13%). Standard dose means a scheduled IFN-α dose of 5 MIU m2/d, but many patients received a dose lower than scheduled, especially in the British study.8 Low dose means a scheduled IFN-α dose at most 3 MIU/d.